B
Bull
Bull · 25%PRFX
$1.94
Szenariopreis
$0.961
-0.025 (-2.60%)Zum Schluss
Loading chart…
- High
- 1.015
- Open
- 0.990
- VWAP
- 0.97
- Vol
- 41.97K
- Mkt Cap
- 1.23M
- Low
- 0.942
- Amount
- 40.83K
- EV/EBITDA, TTM
- 0.00
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
AI analysis of PRF Technologies Ltd (PRFX)
sellPainReform Ltd (PRFX) is not a good buy right now due to its current price of $0.96, a significantly negative year-to-date change of -72.50%, and a concerning forward P/E ratio of 0, indicating a lack of expected earnings growth. The main risk is the company's projected net margin for Q4 2025, which is -29541.18%, suggesting severe profitability issues.
Bewertungskennzahlen
The current forward P/E ratio for PRF Technologies Ltd (PRFX) is 0.00, compared to its 5-year average forward P/E of -2.23.
Alphio AI Price Scenarios for PRFX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.507-27GlobenewswirePRF Technologies Issues Shareholder Letter, Raises $10 Million
9.507-27NewsfilterPRF Technologies Reports First Half 2026 Highlights
- 8.507-21Newsfilter
PRF Technologies to Showcase GridFeed at Energy Trading Week Europe
- 2.007-15Newsfilter
PRF Technologies Expands DeepSolar Predict Platform with New Battery-to-Revenue Intelligence
- 8.507-08Newsfilter
PRF Technologies Completes Initial Validation of DeepSolar Predict
PRFX FAQ — answered by Alphio AI
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
PainReform Ltd (PRFX) is not a good buy right now due to its current price of $0.96, a significantly negative year-to-date change of -72.50%, and a concerning forward P/E ratio of 0, indicating a lack of expected earnings growth. The main risk is the company's projected net margin for Q4 2025, which is -29541.18%, suggesting severe profitability issues.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.